On Thursday, Lexington Realty Trust (NYSE:LXP)’s shares inclined 1.27% to $8.75.
Lexington Realty Trust (LXP), a real estate investment trust (REIT) focused on single-tenant real estate investments, declared it would release its second quarter 2015 results the morning of Tuesday, August 4, 2015. Lexington will conduct a teleconference that same day at 11:00 a.m., Eastern Time.
Lexington Corporate Properties Trust operates as a self-managed and self-administered real estate investment trust (REIT). The company acquires, owns, and manages a portfolio of office, industrial, and retail properties net-leased to corporate tenants in the United States. It also provides investment advisory and asset administration services to institutional investors in the net lease area. As of June 30, 2005, the company operated 185 properties and managed 2 properties. Lexington Corporate Properties Trust has elected to qualify as a REIT for federal income tax purposes.
Ameren Corp (NYSE:AEE)’s shares gained 1.72% to $39.66.
Warner L. Baxter, chairman, president and CEO of Ameren Corp. (AEE), will join Martin J. Lyons, executive vice president and CFO of Ameren Corp., to talk about second quarter 2015 earnings and other matters related to the company in a conference call with financial analysts on Friday, July 31, at 9 a.m. Central Time (10 a.m. Eastern Time).
Ameren Corporation operates as a public utility holding company in the United States. The company engages in the rate-regulated electric generation, transmission, and distribution; and rate-regulated natural gas transmission and distribution businesses. It primarily generates electricity through coal, solar, wind, nuclear power, natural gas, methane gas, hydroelectric power, and oil.
At the end of Thursday’s trade, YY Inc (ADR) (NASDAQ:YY)‘s shares surged 1.69% to $58.53.
YY Inc. (YY) a revolutionary real-time interactive social platform, recently declared that in response to the formerly declared preliminary non-binding proposal (the “Proposal”) contained in a letter dated July 9, 2015 that the Company’s board of directors (the “Board”) received from Mr. Jun Lei, Chairman of the Board, and Mr. David Xueling Li, director and Chief Executive Officer of YY (together, the “Buyer Group”) proposing a “going-private” transaction to acquire all of the outstanding ordinary shares of YY not already beneficially owned by the Buyer Group, the Board has formed a special committee of independent and disinterested directors (the “Special Committee”) to review and evaluate the Proposal.
The Special Committee is composed of Mr. Peter Andrew Schloss, Mr. David Tang, and Mr. Peng Tsing Ong, who are independent directors of the Company and are unassociated with the Proposal. Mr. Schloss will be the chairman of the Special Committee. The Board also authorized the Special Committee to, and anticipates that the Special Committee will, retain independent advisors, counting independent financial and legal advisors, to assist it in the process of reviewing and evaluating the Proposal.
YY Inc., through its auxiliaries, operates an online social platform in the People’s Republic of China. It engages users in real-time online group activities through voice, video, and text on personal computers and mobile devices; and enables users to create and organize groups of various sizes to discover and take part in a range of online activities, counting music shows, online games, dating shows, live games broadcasting, and e-learning. The company’s core product is YY Client, which enables users to engage in live interactions online; and provides access to user-created online social activities groups.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC), ended its Thursday’s trading session with 2.69% gain, and closed at $138.75.
Anacor Pharmaceuticals, Inc. (ANAC) declared preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. In both studies, crisaborole achieved statistically noteworthy results on all primary and secondary endpoints and demonstrated a safety profile comprising with previous studies.
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
